For the year ending 2025-12-31, CAMP had $46,094K increase in cash & cash equivalents over the period. -$29,832K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -80,403 |
| Depreciation and amortization | 1,639 |
| Stock-based compensation expense | 3,998 |
| Change in fair value of derivative tranche liability | -29,830 |
| Impairment of right-of-use asset | 494 |
| Loss on the sale of property and equipment | -258 |
| Non-cash gain on lease modification | 316 |
| Non-cash lease expense | 1,923 |
| Non-cash interest expense | 16 |
| Prepaid expenses and other current assets | 888 |
| Accounts payable | -1,028 |
| Accrued expenses and other liabilities | 805 |
| Operating lease assets and liabilities | 2,996 |
| Deferred revenue | 17,115 |
| Net cash used in operating activities | -29,553 |
| Purchases of property and equipment | 279 |
| Proceeds from the sale of property and equipment | 36 |
| Net cash used in investing activities | -243 |
| Proceeds from issuance of common stock, net of issuance costs of 3,966 and 5,747, respectively | 57,516 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs 258 | 3,601 |
| Proceeds allocated to the derivative tranche liability | 14,930 |
| Proceeds from exercise of common stock options | 51 |
| Principal payments on financing obligation | 97 |
| Principal payments on finance leases | 111 |
| Payments of deferred issuance costs | 0 |
| Net cash provided by financing activities | 75,890 |
| Net increase in cash, cash equivalents and restricted cash | 46,094 |
| Cash, cash equivalents and restricted cash at beginning of year | 65,663 |
| Cash, cash equivalents and restricted cash at end of period | 111,757 |
Camp4 Therapeutics Corp (CAMP)
Camp4 Therapeutics Corp (CAMP)